CHILDREN'S CANCER STUDY GROUP

北京大学儿科血液肿瘤学系 密歇根州在儿童癌症的所有开放性研究中进行合作 研究小组，目标是改善护理和生存 患癌症的儿童。 该科有六名全职临床医生， 研究人员与教师任命的大学 密歇根医学院，以及一个积极的奖学金计划 在儿科血液学-肿瘤学方面， 一年三年。 100至150名新感染者 诊断的癌症从我们的部门与CCSG登记， 年 入组CCSG治疗研究的患者数量 过去三年每年都超过80名病人 在 此外，我们目前正在跟踪393名患者， 需要提交CCSG研究数据。 此外，要 密歇根大学的治疗性研究患者入组 是在开放式网络上招募患者的机构领导者之一， 流行病学研究和其他专门研究， 评估接受ALL治疗的患者的神经生理功能 （CCG-105 NP）和口服维持药物的药理学吸收 在ALL（CCG-105PH）中。 此外，密歇根大学是一个 参与第一阶段的CCSG机构的子集 临床试验 共有10名多学科研究者组成委员会， 约会. 两个人是四个治疗的主席 研究委员会，每个委员会监督一项重大临床试验。 博士 哈钦森将担任校长一职 研究者是开放式CCG-521研究的主席， 何杰金氏病和CG-1001（CCG-164）研究， 低风险ALL患者。 海恩博士是两个 目前正在对CCG-984组织细胞增多症-X研究进行随访， CCG-681研究报告，供CCSG参与国际小组 横纹肌肉瘤研究II。 此外，哈钦森博士还担任 CCSG霍奇金研究的协调员。 哈钦森博士目前 探索开放他的制度研究的可能性， 放射性标记的间碘苄胍治疗 神经母细胞瘤患者参加CCSG。 哈纳什博士是 与癌症生物学委员会和 白血病诊断委员会相对使用他的两个- 三维凝胶电泳技术分析白血病细胞 CCSG研究中的细胞蛋白。 博士 McKeever是CCG-961研究的神经病理学家， 委员会，正在开发一项CCSG研究， 低级别星形细胞瘤的预后因素 Waskerwitz女士 夫人伦纳德，两位临床护士，将继续他们的非常 在CCSG护理委员会和其他几个 学习委员会。 此外，密歇根大学计划 继续大力支持CCSG的所有活动。

The Division of Pediatric Hematology-Oncology of the University of Michigan collaborates in all open studies of the Children's Cancer Study Group, with the goal of improving the care and the survival of children with cancer. The Division has six full-time clinical investigators with faculty appointments at the University of Michigan Medical School, as well as an active fellowship program in pediatric hematology-oncology with three fellows in training per year for three years. Between 100 and 150 patients with newly diagnosed cancer are registered from our Division with CCSG per year. The number of patients entered on CCSG therapeutic studies has exceeded 80 patients for each of the last three years. In addition, we are currently following 393 patients for whom the submission of CCSG study data is required. In addition, to therapeutic study enrollment of patients the University of Michigan is among the institutional leaders in enrolling patients on open epidemiological studies and on other special studies such as those assessing neurophyschologic function in patients treated for ALL (CCG-105NP) and pharmacologic absorption of oral maintenance drugs in ALL (CCG-105PH). Furthermore, the University of Michigan is one of a subset of CCSG institutions which participate in phase I clinical trials. A total of 10 multidisciplinary investigators have committee appointments. Two individuals are the chairmen of four therapeutic study committees, each overseeing a major clinical trial. Dr. Hutchinson who will be assuming the position of principal investigator is chairman of the open CCG-521 Study for advanced Hodgkin's disease and the CG-1001 (CCG-164) Study which is proposed for patients with low-risk ALL. Dr. Heyn is chairman of two studies now in follow-up the CCG-984 Study for histiocytosis-X and the CCG-681 Study for CCSG participation in the Intergroup Rhabdomyosarcoma Study II. In addition, Dr. Hutchinson serves as coordinator of CCSG Hodgkin's studies. Dr. Hutchinson is presently exploring the possibility of opening his institutional study of the therapeutic efficacy or radiolabelled metaiodobenzylguanidine for patients with neuroblastoma to CCSG participation. Dr. Hanash is collaborating with members of the Cancer Biology Committee and the Leukemia Diagnosis Committee relative to the use of his two- dimensional gel electrophoretic technique for analysis of leukemic cellular proteins in CCSG studies of patients with ALL. Dr McKeever, a neuropathologist and member of the CCG-961 Study Committee, is developing a CCSG study addressing neuropathologic prognostic factors in low grade astrocytomas. Ms. Waskerwitz and Mrs. Leonard, the two nurse clinicians, will continue their very active roles within the CCSG Nursing Committee and on several other study committees. Furthermore, the University of Michigan plans to continue its prior strong support of all CCSG activities.